Xeltis AG:医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Xeltis AG - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C10443
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Xeltis AG (Xeltis) is a clinical-stage medical equipment company that harnesses advances in science to improve the treatment of heart valve related conditions. The company’s polymer-based technology platform, RestoreX, facilitates the natural restoration of heart valve through a process referred to as endogenous tissue restoration (ETR). Based on supramolecular chemistry, the company develops bioabsorbable synthetic heart valves and vascular grafts to replace defective heart valves and blood vessels. ETR enables the patient’s natural healing system to develop tissue that spreads into the heart valve of Xeltis, building a new and natural valve inside with full functionality. The implants of Xeltis get absorbed by the body in the course of time. The company also operates research and development centers, manufacturing facility in Eindhoven, the Netherlands. Xeltis is headquartered in Zurich, Switzerland.

Xeltis AG – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Xeltis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Xeltis AG, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Xeltis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Xeltis AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Xeltis AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Xeltis AG, Medical Equipment, Deal Details 10
Venture Financing 10
Xeltis Raises USD52.8 Million in Series C Financing 10
Xeltis Raises Additional USD3.3 Million in Series B Venture Financing 12
Xeltis Raises USD34 Million in Series B Venture Financing 13
Merger 14
Xeltis Merges With Qtis, Maker Of Cardiovascular Implants 14
Xeltis AG – Key Competitors 15
Xeltis AG – Key Employees 16
Xeltis AG – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Corporate Communications 18
May 02, 2017: Professor Lange joins Xeltis’ Medical Advisory Board 18
Apr 21, 2017: Xeltis wins Gold Edison Award in medical technology 19
Mar 15, 2017: Xeltis shortlisted for Company of the Year 20
Feb 09, 2017: Xeltis is a 2017 Edison Awards Finalist 21
Product News 22
Jun 25, 2018: The Children’s Hospital of Pittsburgh of UPMC joins the Xplore-2 trial 22
Jun 22, 2018: Children’s Hospital Los Angeles joins the Xplore-2 Study 23
Jun 13, 2018: Xeltis restorative technology for aortic valves at ISMICS 24
May 14, 2018: Xeltis’ restorative technology at ICTEHV 25
Apr 13, 2018: Xeltis’ restorative aortic valves show promise at HVS 26
Apr 06, 2018: Xeltis’ restorative aortic valves at HVS 27
Sep 26, 2017: ETR featured in peer-reviewed journal EuroIntervention 28
Sep 22, 2017: Xeltis CTO on the future of heart valve therapy at PCR London Valves 29
May 08, 2017: Xeltis CTO at Biomedica Summit 30
Apr 05, 2017: Potential of new cardiovascular restoration strategies presented at SFB 31
Apr 04, 2017: Xeltis data on cardiovascular restoration with electrospun polymers at SFB 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Xeltis AG, Medical Equipment, Key Facts 2
Xeltis AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Xeltis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Xeltis AG, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Xeltis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Xeltis AG, Deals By Market, 2012 to YTD 2018 8
Xeltis AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Xeltis Raises USD52.8 Million in Series C Financing 10
Xeltis Raises Additional USD3.3 Million in Series B Venture Financing 12
Xeltis Raises USD34 Million in Series B Venture Financing 13
Xeltis Merges With Qtis, Maker Of Cardiovascular Implants 14
Xeltis AG, Key Competitors 15
Xeltis AG, Key Employees 16
Xeltis AG, Subsidiaries 17

List of Figures
Xeltis AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Xeltis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Xeltis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Xeltis AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Xeltis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Xeltis AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Xeltis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Xeltis AG, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Xeltis AG:医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Global Insurance Management Limited:企業の戦略・SWOT・財務分析
    Global Insurance Management Limited - Strategy, SWOT and Corporate Finance Report Summary Global Insurance Management Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Waste Management Inc (WM):企業の財務・戦略的SWOT分析
    Waste Management Inc (WM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Pure Bioscience Inc (PURE)-製薬・医療分野:企業M&A・提携分析
    Summary Pure Bioscience Inc (Pure) is involved in the development and commercialization of proprietary antimicrobial products. It develops and markets proprietary antimicrobial products principally in the food safety field providing solutions to the health and environmental challenges of pathogen an …
  • Bando Chemical Industries, Ltd. (5195):企業の財務・戦略的SWOT分析
    Bando Chemical Industries, Ltd. (5195) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Essilor International Compagnie Generale d’Optique SA (EI):医療機器:M&Aディール及び事業提携情報
    Summary Essilor International Compagnie Generale d'Optique SA (Essilor) designs, manufactures and distributes ophthalmic lenses, sunwear, reading glasses and optics equipment. The company offers a range of corrective lenses for correcting visual disorders such as myopia, hypermetropia and astigmatis …
  • Natco Pharma Ltd (NATCOPHARM):製薬・医療:M&Aディール及び事業提携情報
    Summary Natco Pharma Ltd (Natco Pharma) focuses on the research, development, manufacture and commercialization of pharmaceutical substances and finished dosage forms. The company offers finished dosage forms in capsule, injection and tablet. Its products are indicated to treat multiple sclerosis, i …
  • ALTANA AG:企業のM&A・事業提携・投資動向
    ALTANA AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ALTANA AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Waste Management Inc (WM):電力:M&Aディール及び事業提携情報
    Summary Waste Management Inc (WM) is a provider of waste management environmental services. The company has presence in the waste management vertical from collection, solid and hazardous waste landfills management, transfer, recycling and resource recovery, to disposal. Through its personal counseli …
  • Radius Health Inc (RDUS):製薬・医療:M&Aディール及び事業提携情報
    Summary Radius Health Inc (Radius Health), formerly NuVios, Inc., is a biopharmaceutical company that develops and commercializes therapeutics for osteoporosis, oncology and endocrine diseases. The company’s product includes abaloparatide injection, which is used for the treatment of postmenopausal …
  • GSS Infotech Limited (GSS):企業の財務・戦略的SWOT分析
    GSS Infotech Limited (GSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Nanovis Inc:医療機器:M&Aディール及び事業提携情報
    Summary Nanovis Inc (Nanovis) is a medical device company that develops and markets tissue regenerating implants for bone and soft tissues. The company offers products such as implant nanosurfaces, implantable scaffolds and cervical plate, lumbar PEEK interbody systems, pedicle screws, injectable bi …
  • Pharnext SA (ALPHA):企業の財務・戦略的SWOT分析
    Summary Pharnext SA (Pharnext), formerly Pharnext SAS is a biopharmaceutical company that develops novel therapies for severe neurodegenerative diseases. The company offers pleotherapy, a proprietary research and development platform based on network pharmacology that uses wide genomic data to ident …
  • Heroux-Devtek Inc:企業の戦略・SWOT・財務分析
    Heroux-Devtek Inc - Strategy, SWOT and Corporate Finance Report Summary Heroux-Devtek Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Advantage Oil & Gas Ltd. (AAV)-石油・ガス分野:企業M&A・提携分析
    Summary Advantage Oil & Gas Ltd. (Advantage Oil) is an upstream company that exploits, develops, acquires, and produces natural gas and liquids in Alberta. Its exploitation and development program is focused at Glacier. The company’s acreage is spread throughout the Western Canadian Sedimentary Basi …
  • University of Bath:製薬・医療:M&Aディール及び事業提携情報
    Summary University of Bath (UOB) is an educational institution that provides educational and research services. The institute provides under graduate and post graduate programs in the fields of science, engineering and design, humanities and social sciences, and management studies. It also conducts …
  • Enanta Pharmaceuticals Inc (ENTA):企業の財務・戦略的SWOT分析
    Summary Enanta Pharmaceuticals Inc (Enanta) is a biotechnology company. It discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s lead product candidate includes EDP-305, a farnesoid X receptor (FXR) agonist intended for the treatment of n …
  • The United India Insurance Co Ltd:企業の戦略・SWOT・財務情報
    The United India Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report Summary The United India Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Doosan Corporation:企業の戦略・SWOT・財務情報
    Doosan Corporation - Strategy, SWOT and Corporate Finance Report Summary Doosan Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • GFH Financial Group BSC (GFH):企業の財務・戦略的SWOT分析
    GFH Financial Group BSC (GFH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Hepion Pharmaceuticals Inc (HEPA):企業の財務・戦略的SWOT分析
    Summary Hepion Pharmaceuticals Inc (Hepion) formerly known as ContraVir Pharmaceuticals Inc, is a biopharmaceutical company that offers development and commercialization of targeted antiviral therapies. The company provides pipeline product such as TXL, potent prodrug of antiviral tenofovir and CRV4 …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆